Journal Article Epublish 17 citations
PubMed: 38350963 DOI: 10.1186/s12906-024-04381-w
Green-synthesized silver nanoparticles from Zingiber officinale extract: antioxidant potential, biocompatibility, anti-LOX properties, and in silico analysis.
BMC Complement Med Ther 24(1):84
Authors: Tassanee Ongtanasup, Patipat Kamdenlek, Chawan Manaspon, Komgrit Eawsakul
Affiliations
- Department of Applied Thai Traditional Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat, 80160, Thailand.
- Biomedical Engineering Institute, Chiang Mai University, Chiang Mai, 50200, Thailand.
- Biomedical Engineering and Innovation Research Center, Chiang Mai University, Chiang Mai, 50200, Thailand.
- Department of Applied Thai Traditional Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat, 80160, Thailand.
- Research Excellence Center for Innovation and Health Products (RECIHP), Walailak University, Nakhon Si Thammarat, 80160, Thailand.
Abstract
INTRODUCTION
Zingiber officinale extract has emerged as a compelling candidate for green synthesis of nanoparticles, offering diverse applications across medicine, cosmetics, and nutrition. This study delves into the investigation of in vitro toxicity and explores the biomedical utility of green-synthesized silver nanoparticles derived from ginger extract (GE-AgNPs).
METHODS
We employed established protocols to evaluate in vitro aspects such as antioxidant capacity, anti-inflammatory potential, and biocompatibility of GE-AgNPs. Additionally, molecular docking was employed to assess their anti-lipoxygenase (anti-LOX) activity.
RESULTS
Our findings highlight that the extraction of ginger extract at a pH of 6, utilizing a cosolvent blend of ethanol and ethyl acetate in a 1:1 ratio, yields heightened antioxidant capacity attributed to its rich phenolic and flavonoid content. In the context of silver nanoparticle synthesis, pH 6 extraction yields the highest quantity of nanoparticles, characterized by an average size of 32.64 ± 1.65 nm. Of particular significance, GE-AgNPs (at pH 6) demonstrated remarkable efficacy in scavenging free radicals, as evidenced by an IC value of 6.83 ± 0.47 µg/mL. The results from the anti-LOX experiment indicate that GE-AgNPs, at a concentration of 10 µg/mL, can inhibit LOX activity by 25%, outperforming ginger extract which inhibits LOX by 17-18%. Notably, clionasterol exhibited higher binding energy and enhanced stability (-8.9 kcal/mol) compared to nordihydroguaiaretic acid. Furthermore, a cell viability study confirmed the safety of GE-AgNPs at a concentration of 17.52 ± 7.00 µg/mL against the L929 cell line.
CONCLUSION
These comprehensive findings underscore the significant biomedical advantages of GE-AgNPs and emphasize their potential incorporation into cosmetic products at a maximum concentration of 10 µg/mL.
MeSH
Complementary Therapies, Antioxidants, Cells, Nanoparticles
Cited by
- Synergistic anticancer potential of biogenic nanoparticles and cryptomeridiol from : targeting gastric cancer through apoptosis and cell cycle arrest. Front Pharmacol, 2025
- Flavonoids as key players in cold tolerance: molecular insights and applications in horticultural crops. Hortic Res, 2025
- Potential effect of phyto-synthesized silver nanoparticles using Cotula cinerea Del Raw extract on salt tolerance of wheat seeds (Triticum durum desf, Boussellam variety) germination. Sci Rep, 2025
- Evaluation of the antibacterial efficacy of combinations of Garcinia mangostana, Curcuma comosa, and Acanthus ebracteatus for acne vulgaris treatment: in Silico and in vitro validation. BMC Complement Med Ther, 2025
- A review on green synthesis of silver nanoparticles (SNPs) using plant extracts: a multifaceted approach in photocatalysis, environmental remediation, and biomedicine. RSC Adv, 2025
- Comparative efficacy of extract delivery PEG--PCL, niosome, and their combination against genotype T4: characterization, inhibition, anti-adhesion, and cytotoxic activity. PeerJ, 2024
- In-Vitro Bioactive Silver Nanoparticles Synthesized from Plant Extract for Multifunctional Drug Delivery. ACS Omega, 2025